Diagnostic Study of the EMVision Emu™ Brain Scanner for Stroke
This study is evaluating a new device called the EMVision emu™ Brain Scanner. This scanner uses radio waves to look for bleeding in the brain (hemorrhagic stroke) in people who might be having a stroke. Strokes happen when blood flow to the brain is interrupted, either by a clot or bleeding, and quick diagnosis is very important. Currently, CT or MRI scans are used, but they aren't always available. The emu™ Brain Scanner is a portable, helmet-like device that aims to be more accessible. Researchers want to see if the emu™ Brain Scanner can detect bleeding in the brain with over 80% accuracy compared to standard CT or MRI scans. You may be able to join if you are an adult aged 22 or older, suspected of having a stroke within 24 hours of symptoms, and your head fits the scanner. The study is currently recruiting 300 participants.
- Study design
- This is an observational study comparing the EMVision emu™ Brain Scanner's results to standard CT or MRI scans in 300 participants. It is not specified if it is blinded or randomized.
- What's involved
- You would receive a scan with the EMVision emu™ Brain Scanner. This happens alongside your usual stroke care, so it won't delay your treatment. You will also have standard CT or MRI brain imaging.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary goal is to measure the scanner's accuracy within 30 minutes of a standard CT/MRI. No further follow-up is specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
At a glance
Conditions
NCT06999122
Where you'd take part
This study runs at 8 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Liverpool Hospital
Liverpool, New South Wales, Australiastudy coordinator listed
Recruiting
Mayo Jacksonville
Jacksonville, Floridastudy coordinator listed
Recruiting
Memorial Hermann Memorial City Medical Center
Houston, Texasstudy coordinator listed
Recruiting
Mount Sinai Health System
New York, New Yorkstudy coordinator listed
Recruiting
Mount Sinai West
New York, New Yorkstudy coordinator listed
Recruiting
Royal Melbourne Hospital
Parkville, Victoria, Australiastudy coordinator listed
Recruiting
UCLA
Los Angeles, Californiastudy coordinator listed
Recruiting
UTHealth
Houston, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Reade De Leacy, MBBS(Hons) FRANZCR · PRINCIPAL_INVESTIGATOR · Associate Professor of Neurosurgery and Radiology Director of Neurointerventional Spine Site Director Cerebrovascular Services Mount Sinai Queens Co-director Neuroendovascular Surgery Fellowship Department of Neurosurgery Mount Sinai Health System
- Angela Dos Santos, PhD · PRINCIPAL_INVESTIGATOR · Melbourne Health
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Demonstrate haemorrhage detection sensitivity >80% and specificity >80%<30 minutes from acute baseline CT/MRI